Ayala Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ayala Pharmaceuticals, Inc.
Advaxis To Seek New Life In Merger With Ayala
The new company will focus mainly on Ayala’s lead candidate for desmoid tumors, but minority owner Advaxis will take over management.
Ayala In Shadow Of SpringWorks In Rare Cancer Race
The companies’ respective gamma-secretase inhibitors provided positive data for desmoid tumors at the ESMO congress but SpringWork’s nirogacestat impressed the most.
SpringWorks Targets Rare Tumors, But Myeloma Is The Mother Lode
The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.
Moderna Shone As COVID-19 Breakthroughs Were Rewarded At The 17th Annual Scrip Awards
The pharma, biotech and allied industries came back together in London on 2 December to celebrate a year of exceptional achievement at the 17th Annual Scrip Awards, hosted by the journalist and broadcaster Amol Rajan.
Drug Discovery Technologies
- Drug Discovery Technologies
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.